The overall prevalence of frailty amongst this demographic is estimated to be 7.9% 
- The overall prevalence of frailty amongst this demographic is estimated to be 7.9% 
Lomecel-B has been evaluated in Phase 1 & 2 aging frailty clinical studies in the U.S.
- A Phase 2 clinical trial is currently underway in babies with HLHS.
- The Japanese Phase 2 study is a randomized, double-blind, placebo-controlled design approved by Japans Pharmaceuticals and Medical Devices Agency (PMDA).
- Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).